130 crore mark but has failed to do so. As per the latest calculations, ‘Game Changer’ stands at Rs.128.05 crore net collection in India.
Spravato was already available in the market before today's FDA approval and has already proven to be a financial success for J&J but only as an adjunct therapy to oral antidepressants for TRD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results